Mark Frohlich, Indapta Therapeutics CEO

Cell ther­a­py pi­o­neer Mark Frohlich takes the helm at tiny In­dap­ta as a suite of big-name back­ers jump aboard

Off-the-shelf cell ther­a­py has be­come a red-hot field of in­vest­ment in re­cent years as the first rounds of hu­man da­ta start rolling out. Now, cell …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.